

Michael Houghton

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8982326/michael-houghton-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

19,706
citations

70
h-index

139
g-index

190
ext. papers

21,043
ext. citations

9.9
avg, IF

5.94
L-index

#	Paper	IF	Citations
179	Binding of hepatitis C virus to CD81. <i>Science</i> , 1998 , 282, 938-41	33.3	1547
178	Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. <i>New England Journal of Medicine</i> , 1989 , 321, 1494-500	59.2	1460
177	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994 , 19, 1321-1324	1.2	854
176	Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. <i>Hepatology</i> , 1991 , 14, 381-388	11.2	734
175	Analysis of a successful immune response against hepatitis C virus. <i>Immunity</i> , 1999 , 10, 439-49	32.3	689
174	Structure, sequence and expression of the hepatitis delta (delta) viral genome. <i>Nature</i> , 1986 , 323, 508-14	30.4	615
173	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991 , 180, 842-8	3.6	537
172	Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1645-55	16.6	512
171	Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. <i>Journal of Clinical Investigation</i> , 1996 , 98, 706-14	15.9	512
170	Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. <i>Lancet, The</i> , 1991 , 337, 317-9	4.0	457
169	The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. <i>Immunity</i> , 2001 , 15, 883-95	32.3	336
168	Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 1711-5	11.5	329
167	Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 2755-9	11.5	298
166	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. <i>Gastroenterology</i> , 1993 , 104, 580-7	13.3	297
165	A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 1759-63	11.5	296
164	Prospects for a vaccine against the hepatitis C virus. <i>Nature</i> , 2005 , 436, 961-6	50.4	270
163	A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. <i>Cancer</i> , 1991 , 67, 429-33	6.4	270

162	Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. <i>Journal of Clinical Investigation</i> , 1995 , 95, 521-30	15.9	259
161	The way forward in HCV treatment--finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007 , 6, 991-1000	10.0	243
160	Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. <i>Journal of Virology</i> , 1997 , 71, 6011-9	6.6	240
159	Vertical transmission of hepatitis C virus. <i>Lancet, The</i> , 1991 , 338, 17-8	4.0	238
158	Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. <i>Journal of Clinical Investigation</i> , 1996 , 98, 1432-40	15.9	233
157	HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. <i>Journal of Clinical Investigation</i> , 1995 , 96, 2311-21	15.9	231
156	Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 18544-9	11.5	223
155	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. <i>Journal of Experimental Medicine</i> , 1993 , 178, 17-25	16.6	221
154	Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. <i>Journal of Virology</i> , 1996 , 70, 7092-102	6.6	215
153	Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. <i>Lancet, The</i> , 1990 , 335, 873-4	4.0	214
152	Hepatitis C antibody and chronic liver disease in haemophilia. <i>Lancet, The</i> , 1990 , 335, 1117-9	4.0	204
151	Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. <i>Hepatology</i> , 2001 , 33, 1479-87	11.2	176
150	The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 192, 399-406	3.4	173
149	Structure-function analysis of hepatitis C virus envelope-CD81 binding. <i>Journal of Virology</i> , 2000 , 74, 4824-30	6.6	172
148	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. <i>Vaccine</i> , 2010 , 28, 6367-73	4.1	155
147	Association of hepatitis C virus envelope proteins with exosomes. <i>European Journal of Immunology</i> , 2004 , 34, 2834-42	6.1	155
146	Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. <i>Journal of Virology</i> , 1993 , 67, 6753-61	6.6	154
145	A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. <i>Nucleic Acids Research</i> , 1989 , 17, 10367-72	20.1	145

144	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- α b. <i>Hepatology</i> , 1993 , 18, 1300-1305	11.2	144
143	Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. <i>Gastroenterology</i> , 1992 , 103, 622-9	13.3	143
142	Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. <i>Gastroenterology</i> , 1999 , 117, 926-32	13.3	133
141	Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. <i>Journal of Infectious Diseases</i> , 1997 , 176, 859-66	7	126
140	High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. <i>Hepatology</i> , 1998 , 28, 1117-20	11.2	126
139	Hepatitis C virus core and E2 protein expression in transgenic mice. <i>Hepatology</i> , 1997 , 25, 719-27	11.2	120
138	Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. <i>Journal of Virology</i> , 2003 , 77, 810-2	6.6	118
137	Complex processing and protein:protein interactions in the E2:NS2 region of HCV. <i>Virology</i> , 1994 , 204, 114-22	3.6	118
136	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. <i>Hepatology</i> , 1993 , 18, 497-502	11.2	118
135	A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. <i>PLoS ONE</i> , 2013 , 8, e59776 ³⁻⁷		112
134	Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. <i>Immunological Reviews</i> , 2011 , 239, 99-108	11.3	112
133	The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. <i>Emerging Microbes and Infections</i> , 2014 , 3, e51	18.9	109
132	Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. <i>Virology</i> , 1992 , 188, 819-30	3.6	109
131	Immune responses to plasmid DNA encoding the hepatitis C virus core protein. <i>Journal of Virology</i> , 1995 , 69, 5859-63	6.6	108
130	Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. <i>Journal of Clinical Microbiology</i> , 1992 , 30, 3220-4	9.7	101
129	A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. <i>Journal of Virology</i> , 1993 , 67, 4365-8	6.6	100
128	Activation of the grp78 and grp94 promoters by hepatitis C virus E2 envelope protein. <i>Journal of Virology</i> , 1999 , 73, 3718-22	6.6	99
127	Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. <i>Journal of Clinical Microbiology</i> , 1991 , 29, 2528-34	9.7	98

126	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. <i>Virus Research</i> , 2018 , 248, 53-62	6.4	95
125	The long and winding road leading to the identification of the hepatitis C virus. <i>Journal of Hepatology</i> , 2009 , 51, 939-48	13.4	94
124	Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. <i>Journal of Virology</i> , 2004 , 78, 10328-35	6.6	94
123	Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. <i>Journal of Immunology</i> , 2001 , 166, 3589-98	5.3	94
122	Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. <i>Hepatology</i> , 2000 , 32, 597-603	11.2	91
121	Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. <i>Nucleic Acids Research</i> , 1990 , 18, 4626	20.1	84
120	Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. <i>Journal of Virology</i> , 1995 , 69, 32-8	6.6	83
119	Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. <i>Journal of Virology</i> , 1997 , 71, 2241-51	6.6	83
118	Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. <i>Hum Vaccin</i> , 2009 , 5, 151-7		80
117	Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1186-90	7	79
116	Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. <i>Journal of Infectious Diseases</i> , 2010 , 202, 862-6	7	79
115	Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. <i>Journal of Virology</i> , 2001 , 75, 7142-8	6.6	78
114	Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1992 , 15, 187-90	11.2	77
113	Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. <i>Nature Medicine</i> , 2000 , 6, 1082-6	50.5	76
112	Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. <i>Gene</i> , 1990 , 91, 287-91	3.8	75
111	IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. <i>PLoS Pathogens</i> , 2014 , 10, e1004556	7.6	72
110	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. <i>Vaccine</i> , 2007 , 25, 7773-84	4.1	70
109	Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. <i>Journal of General Virology</i> , 2000 , 81, 2451-2459	4.9	67

108	Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. <i>Virology</i> , 2005 , 332, 438-53	3.6	65
107	Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. <i>Journal of Virology</i> , 2000 , 74, 6885-92	6.6	65
106	5'Send-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5'Suntranslated region. <i>Virology</i> , 1992 , 191, 889-99	3.6	65
105	Cationic microparticles are a potent delivery system for a HCV DNA vaccine. <i>Vaccine</i> , 2004 , 23, 672-80	4.1	64
104	HCV testing in low-risk population. <i>Lancet, The</i> , 1990 , 336, 695	4.0	63
103	Discovery of the hepatitis C virus. <i>Liver International</i> , 2009 , 29 Suppl 1, 82-8	7.9	61
102	Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. <i>Hepatology</i> , 2001 , 33, 1312-20	11.2	60
101	Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2014 , 210, 717-27	7	59
100	Prevalence of anti-HCV antibody in blood donors in the Tokyo area. <i>Vox Sanguinis</i> , 1990 , 59, 86-8	3.1	59
99	Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. <i>Scientific Reports</i> , 2019 , 9, 12392	4.9	57
98	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8 T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 1215	8.4	55
97	Hepatitis C virus replication in SautoimmuneSchronic hepatitis. <i>Journal of Hepatology</i> , 1991 , 13, 364-7	13.4	55
96	Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. <i>Journal of Virology</i> , 2014 , 88, 14278-88	6.6	53
95	Early antihepatitis C virus response with second-generation C200/C22 ELISA. <i>Vox Sanguinis</i> , 1992 , 62, 208-12	3.1	53
94	Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. <i>Hepatology</i> , 2013 , 58, 1907-17	11.2	49
93	Induction in vitro of a primary human antiviral cytotoxic T cell response. <i>European Journal of Immunology</i> , 1995 , 25, 627-30	6.1	48
92	Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. <i>Vox Sanguinis</i> , 1992 , 62, 213-7	3.1	47
91	Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. <i>Journal of Virology</i> , 2000 , 74, 7192-503	6.6	46

90	Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. <i>Journal of Infectious Diseases</i> , 2011 , 204, 811-3	7	43
89	Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. <i>Virology</i> , 2002 , 304, 187-96	3.6	42
88	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S6-14	13.4	42
87	Antibody to the hepatitis C virus in acute hepatitis and chronic liver diseases in Japan. <i>Liver</i> , 1991 , 11, 65-70		40
86	Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. <i>Journal of General Virology</i> , 2006 , 87, 2253-2262	4.9	40
85	Folding of hepatitis C virus E1 glycoprotein in a cell-free system. <i>Journal of Virology</i> , 2001 , 75, 11205-17	6.6	40
84	A human ether- γ -go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. <i>Toxicology Letters</i> , 2014 , 230, 382-92	4.4	37
83	Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. <i>Journal of Virology</i> , 2008 , 82, 5109-14	6.6	36
82	Progress towards a hepatitis C virus vaccine. <i>Emerging Microbes and Infections</i> , 2013 , 2, e79	18.9	35
81	Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. <i>Journal of Virology</i> , 1994 , 68, 4420-6	6.6	35
80	Perspectives for a vaccine against hepatitis C virus. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 259-63	13.4	34
79	Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. <i>Annals of Internal Medicine</i> , 1991 , 115, 882-4	8	34
78	Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. <i>Journal of Infectious Diseases</i> , 2001 , 183, 1187-94	7	33
77	A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. <i>Journal of Chemical Information and Modeling</i> , 2015 , 55, 362-73 ^{6.1}		32
76	Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2014 , 34, 204-14	3.5	32
75	Fabrication of flexible self-standing all-cellulose nanofibrous composite membranes for virus removal. <i>Carbohydrate Polymers</i> , 2016 , 143, 9-17	10.3	30
74	Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Cytokine</i> , 2016 , 78, 27-36	4	30
73	Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach. <i>Seminars in Liver Disease</i> , 1992 , 12, 279-88	7.3	28

72	Group specific sequences and conserved secondary structures at the 3' end of HCV genome and its implication for viral replication. <i>Nucleic Acids Research</i> , 1992 , 20, 3520	20.1	28
71	Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. <i>PLoS ONE</i> , 2013 , 8, e68308	3.7	27
70	Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991 , 36, 1130-3	4	27
69	Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. <i>Journal of Virology</i> , 2017 , 91,	6.6	25
68	Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). <i>Journal of Hepatology</i> , 2005 , 42, 499-504	13.4	25
67	Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus. <i>Journal of Virology</i> , 2017 , 91,	6.6	24
66	Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets. <i>ACS Infectious Diseases</i> , 2016 , 2, 749-762	5.5	24
65	Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. <i>Journal of Hepatology</i> , 2013 , 59, 336-43	13.4	24
64	Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis. <i>Gastroenterology</i> , 1991 , 101, 1117-9	13.3	23
63	Glycogen synthase kinase 3 inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism. <i>Scientific Reports</i> , 2017 , 7, 2495	4.9	22
62	Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. <i>PLoS Pathogens</i> , 2020 , 16, e1008515	7.6	22
61	Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. <i>Journal of Virology</i> , 2018 , 92,	6.6	21
60	Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design. <i>Journal of Chemical Information and Modeling</i> , 2013 , 53, 3031-43	6.1	21
59	Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. <i>Journal of Virology</i> , 2006 , 80, 12131-40	6.6	21
58	Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. <i>Drug Discovery Today</i> , 2015 , 20, 548-61	8.8	20
57	Vaccine adjuvants--understanding molecular mechanisms to improve vaccines. <i>Swiss Medical Weekly</i> , 2014 , 144, w13940	3.1	20
56	Minimum data elements for research reports on CFS. <i>Brain, Behavior, and Immunity</i> , 2012 , 26, 401-6	16.6	20
55	Modeling the human Na ^{1.5} sodium channel: structural and mechanistic insights of ion permeation and drug blockade. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 2301-2324	4.4	17

54	Hepatitis C virus: structure, protein products and processing of the polyprotein precursor. <i>Current Studies in Hematology and Blood Transfusion</i> , 1994 , 61, 1-11		17
53	Hepatitis C virus heteroduplex tracking assay for genotype determination reveals diverging genotype 2 isolates in Italian hemodialysis patients. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 227-33	9.7	17
52	Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2015 , 212, 137-46	7	16
51	HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α and Ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 458-65	3.4	15
50	Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. <i>Liver</i> , 1994 , 14, 65-70		15
49	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999 , 31, 990-6	13.4	15
48	An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	14
47	Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. <i>Vaccine</i> , 2000 , 18, 1962-8	4.1	13
46	Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. <i>Vaccines</i> , 2019 , 7,	5.3	13
45	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. <i>Journal of Hepatology</i> , 2019 , 70, 1082-1092	13.4	12
44	Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. <i>Vaccine</i> , 2004 , 22, 457-66	4.1	12
43	Comparison of secretion of a hepatitis C virus glycoprotein in <i>Saccharomyces cerevisiae</i> and <i>Kluyveromyces lactis</i> . <i>Research in Microbiology</i> , 1999 , 150, 179-87	4	12
42	No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. <i>PLoS ONE</i> , 2011 , 6, e27870	3.7	12
41	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. <i>Liver Transplantation</i> , 2016 , 22, 324-32	4.5	12
40	CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfectd with HCV and human immunodeficiency virus who responded to anti-HCV treatment. <i>Journal of Infectious Diseases</i> , 2002 , 186, 302-11	7	11
39	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019 , 70, 593-602	13.4	11
38	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients 1993 , 18, 497		10
37	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. <i>Cell Chemical Biology</i> , 2020 , 27, 780-792.e5	8.2	9

36	A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. <i>Molecular Pharmaceutics</i> , 2013 , 10, 4572-89	5.6	9
35	Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. <i>Gut</i> , 1993 , 34, S124-5	19.2	9
34	A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. <i>ACS Infectious Diseases</i> , 2016 , 2, 872-881	5.5	9
33	Hepatitis C: the next 25years. <i>Antiviral Research</i> , 2014 , 110, 77-8	10.8	8
32	Hepatitis C Virus: 30 Years after Its Discovery. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	7
31	Prospects for a hepatitis C virus vaccine. <i>Clinics in Liver Disease</i> , 1999 , 3, 901-15	4.6	7
30	A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
29	Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA. <i>Hepatology</i> , 2000 , 31, 1327-33	11.2	6
28	A structure-based computational workflow to predict liability and binding modes of small molecules to hERG. <i>Scientific Reports</i> , 2020 , 10, 16262	4.9	6
27	A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase. <i>Journal of Biological Chemistry</i> , 2018 , 293, 9696-9705	5.4	6
26	Use of recombinant HCV antigen in the serodiagnosis of hepatitis C virus infection: Significant improvement in HCV antibody detection as compared with the first generation HCV C100-3 ELISA and the synthetic peptide EIA tests. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993 , 8, S33-S39	4	5
25	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021 , 39, 5769-5779	4.1	4
24	Rational Drug Design. <i>International Journal of Computational Models and Algorithms in Medicine</i> , 2014 , 4, 59-85		3
23	7 Humoral response to hepatitis C virus. <i>Biomedical Research Reports</i> , 2000 , 2, 125-145		3
22	The Hepatitis C Virus: Genetic Organization, Persistence, and Vaccine Strategies 1994 , 33-37		3
21	A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. <i>Journal of Immunological Methods</i> , 2017 , 445, 15-22	2.5	2
20	Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19. <i>BMC Pharmacology & Toxicology</i> , 2021 , 22, 61	2.6	2
19	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021 , 73, 1105-1116	11.2	2

18	Three isn't the magic number. <i>Nature Medicine</i> , 2013 , 19, 807	50.5	1
17	Chimp virus makes a savvy vaccine vector. <i>Science Translational Medicine</i> , 2012 , 4, 115fs1	17.5	1
16	Rabbit-derived anti-HD antibodies for HDAg immunoblotting. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S130-3	13.4	1
15	Hepatitis C virus vaccines 2008 , 1187-1199		1
14	Application of Polymerase Chain Reaction to Hepatitis C Virus Research and Diagnostics. <i>Frontiers of Virology</i> , 1992 , 86-100		1
13	Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2020 , 60, 6566-6578	6.1	1
12	Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs. <i>Canadian Liver Journal</i> , 2020 , 3, 276-285	0.3	0
11	Progress toward approval of an HCV vaccine. <i>Canadian Liver Journal</i> , 2018 , 1, 130-138	0.3	0
10	Structure and Molecular Virology 379-406		0
9	Towards the Control of Hepatitis C 2016 , 3-14		
8	Hepatitis C Vaccines 2018 , 375-385.e5		
7	The Discovery of the Hepatitis C Virus. <i>Topics in Medicinal Chemistry</i> , 2019 , 19-27	0.4	
6	Hepatitis C vaccines 2013 , 1074-1084		
5	Structure and Molecular Virology 2013 , 219-245		
4	Effect of IL-12 on T-cell immune responses in patients with chronic HCV infection. <i>Apmis</i> , 2008 , 108, 531-538		
3	Hepatitis C Virus-specific Cytotoxic T Lymphocytes Restricted by HLA-A2 are Present in the Peripheral Blood of Patients with Chronic Hepatitis C 1994 , 190-194		
2	HCV-positive, HIV-1-negative Mothers Transmit HCV 1994 , 463-467		
1	Progress toward approval of an HCV vaccine. <i>Canadian Liver Journal</i> , 2018 , 1-9	0.3	

